Sex differences in brain tumor glutamine metabolism reveal sex-specific vulnerabilities to treatment
Dr Michael Albert a US internist wrote about taking low-dose tirzepatide for two years in March 2026, framed as a personal choice, not a recommendation [15]
Glucagon-like peptide-1 (GLP-1) receptor agonists, FDA-approved medications for type 2 diabetes and obesity, are increasingly recognized for potential anti-inflammatory properties beyond their metabolic effects
However, specific information about their impact on polycystic ovarian syndrome (PCOS) is currently lacking
The new 7.2mg dose produces approximately 20.7% weight loss, essentially matching Mounjaro 15mg, compared to 14.9% at the standard 2.4mg dose.
Table 1 Current glucagon containing anti-obesity drugs in development